REFERENCES
- Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in prevent-ing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–384.
- Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in per-sons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–733.
- Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy ac-cording to baseline CD4+ T-cell count. J Acauir Immune Defic Syndr 2004;36(2):702–713.
- Centro Operativo AIDS. Istituto Superiore di Sanita. Ag-giornamento dei casi di AIDS notificati in Italia e delle nu-ove diagnosi di infezione da HIV. Available at: http://www.iss.it/binary/pres/cont/Rap%20AIDS%2031%20Dicembre%202004.1129713087.pdf. Accessed August 15,2006.
- Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral ther-apy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327)119–129.
- Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lan-cet 2003;362(9385):679–686.
- d'Arminio MA, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005; 165(4):416–423.
- MacArthur RD, Perez G, Walmsley S, Baxter JD, Mullin CM, Neaton JD. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with ad-vanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005;6(3):127–135.
- Thiebaut R, Chene G, Jacqmin-Gadda H, et al. Time-updated CD4+ T lymphocyte count and HIV RNA as ma-jor markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996–2001. J Acquir Immune Defic Syndr 2003;33(3):380–386.
- Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel JAMA 2004;292(2):251–265.
- Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2006. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentsGL.pdf. Accessed September 14,2006.
- World Health Organization. Scaling up Antiretroviral Ther-apy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: WHO; 2004.
- Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and re-sponses to antiretroviral therapy. AIDS. 2004;18(16):2145–2151.
- Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med. 2004;5(2):93–98.
- Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV ther-apy. J Acquir Immune Defic Syndr 2004;37(1):1147–1154.
- Park WB, Choe PG, Jo JH, et al. Immune reconstitution in-flammatory syndrome in the first year after HAART: influence on long-term clinical outcome AIDS 2006;20(18):2390–2392.
- May MT, Sterne JA, Costagliola D, et al. HIV treatment re-sponse and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a col-laborative analysis. Lancet. 2006;368(9534):451–458.
- El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N End' J Med. 2006;355(22):2283–2296.